Communicable Diseases  >>  moxifloxacin intravenous  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
moxifloxacin intravenous / Generic mfg.
NCT00460759: Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine

Terminated
1
15
US
Moxifloxacin, Rifapentine
Johns Hopkins University
Mycobacterium Tuberculosis
08/08
08/08
NCT00973388: VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Completed
1
44
RoW
Telaprevir; Moxifloxacin; Placebo
Tibotec BVBA, Vertex Pharmaceuticals Incorporated
Hepatitis C
01/10
01/10
NCT01928914: Tafenoquine Thorough QTc Study in Healthy Subjects

Completed
1
260
US
Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg, moxifloxacin, Placebo for Tafenoquine, Placebo for moxifloxaxin
GlaxoSmithKline
Malaria, Vivax
06/12
06/12
NCT01049022 / 2012-000737-40: Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

Completed
1
31
US
Moxifloxacin (Avelox, BAY12-8039)
Bayer
Infections
12/12
08/13

Download Options